RESUMEN
Hepatocyte growth factor (HGF) promotes regeneration of the central nervous system, but its effects on the peripheral nervous system remain unclear. This study was conducted to elucidate the effect of HGF on regeneration of the murine facial nerve after crush injury. To do so, a replication-defective herpes simplex virus vector that incorporated HGF was prepared (HSV-HGF). The main trunk of the facial nerve was compressed by mosquito hemostats, and HSV-HGF, control vector or medium was then applied to the compressed nerve. We found that mice in the HGF group required significantly fewer days for complete recovery from nerve compression. Furthermore, the amplitude of the evoked buccinator muscle compound action potential increased following HSV-HGF application. HGF expression in and around the compressed nerve was demonstrated by enzyme-linked immunoassay and immunohistochemistry. In addition, HSV-HGF introduction around the damaged nerve significantly accelerated recovery of function of the facial nerve. These data suggest a possible role of HGF in promoting facial nerve regeneration after nerve damage. Furthermore, this viral delivery method may be applied clinically for many types of severe facial palsy during facial nerve decompression surgery.
Asunto(s)
Traumatismos del Nervio Facial/terapia , Terapia Genética/métodos , Factor de Crecimiento de Hepatocito/genética , Regeneración Nerviosa/efectos de los fármacos , Simplexvirus/genética , Animales , Nervio Facial/fisiología , Vectores Genéticos , Ratones , Síndromes de Compresión Nerviosa/terapia , Regeneración Nerviosa/genéticaRESUMEN
Radiation-induced cavernous malformations are rarely reported, and most cases have been children. We describe two adult patients with cavernous malformation after irradiation for astrocytoma. Magnetic resonance (MR) imaging, at their ages of 53 years, showed a cavernous malformation in the irradiated field 26 and 10 years after resection and irradiation, respectively. Cavernous malformations were confirmed by the histopathological examination in the both cases. Radiation-induced cavernous malformations are rare in adult patients with astrocytoma. One reason why we found two such cases was that these patients had been successfully treated for astrocytoma and had long follow-up periods.
Asunto(s)
Astrocitoma/radioterapia , Vasos Sanguíneos/patología , Vasos Sanguíneos/efectos de la radiación , Neoplasias Encefálicas/radioterapia , Hemangioma Cavernoso del Sistema Nervioso Central/etiología , Neoplasias Inducidas por Radiación/etiología , Radioterapia/efectos adversos , Astrocitoma/diagnóstico , Vasos Sanguíneos/fisiopatología , Neoplasias Encefálicas/diagnóstico , Neoplasias Cerebelosas/diagnóstico , Neoplasias Cerebelosas/radioterapia , Demencia/diagnóstico , Demencia/etiología , Demencia/fisiopatología , Lóbulo Frontal/irrigación sanguínea , Lóbulo Frontal/patología , Lóbulo Frontal/efectos de la radiación , Hemangioma Cavernoso del Sistema Nervioso Central/diagnóstico , Hemangioma Cavernoso del Sistema Nervioso Central/fisiopatología , Humanos , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Recurrencia Local de Neoplasia , Neoplasias Inducidas por Radiación/diagnóstico , Neoplasias Inducidas por Radiación/fisiopatología , Lóbulo Temporal/irrigación sanguínea , Lóbulo Temporal/patología , Lóbulo Temporal/efectos de la radiación , Tomografía Computarizada por Rayos XRESUMEN
Takagaki, M., Ono, K., Masunaga, S-I., Kinashi, Y., Oda, Y., Miyatake, S-I., Hashimoto, N., Powell, W., Sood, A. and Spielvogel, B. F. Boronated Dipeptide Borotrimethylglycylphenylalanine as a Potential Boron Carrier in Boron Neutron Capture Therapy for Malignant Brain Tumors. Radiat. Res. 156, 118-122 (2001).A boronated dipeptide, borotrimethylglycylphenylalanine (BGPA), was synthesized as a possible boron carrier for boron neutron capture therapy (BNCT) for malignant brain tumors. In vitro, at equal concentrations of (10)B in the extracellular medium, BGPA had the same effect in BNCT as p-boronophenylalanine (BPA). Boron analysis was carried out using prompt gamma-ray spectrometry and track-etch autoradiography. The tumor:blood and tumor:normal brain (10)B concentration ratios were 8.9 +/- 2.1 and 3.0 +/- 1.2, respectively, in rats bearing intracranial C6 gliosarcomas using alpha-particle track autoradiography. The IC(50), i.e. the dose capable of inhibiting the growth of C6 gliosarcoma cells by 50% after 3 days of incubation, was 5.9 x 10(-3) M BGPA, which is similar to that of 6.4 x 10(-3) M for BPA. The amide bond of BGPA is free from enzymatic attack, since it is protected from hydrolysis by the presence of a boron atom at the alpha-carbon position of glycine. These results suggest promise for the use of this agent for BNCT of malignant brain tumors. Further preclinical studies of BGPA are warranted, since BGPA has advantages over both BPA and BSH.
Asunto(s)
Alanina/administración & dosificación , Compuestos de Boro/administración & dosificación , Terapia por Captura de Neutrón de Boro/métodos , Neoplasias Encefálicas/radioterapia , Fructosa/análogos & derivados , Gliosarcoma/radioterapia , Alanina/análogos & derivados , Animales , Autorradiografía , Compuestos de Boro/efectos de la radiación , Encéfalo/efectos de los fármacos , Encéfalo/patología , Encéfalo/efectos de la radiación , Neoplasias Encefálicas/química , Neoplasias Encefálicas/patología , División Celular/efectos de la radiación , Supervivencia Celular/efectos de la radiación , Modelos Animales de Enfermedad , Relación Dosis-Respuesta en la Radiación , Fructosa/administración & dosificación , Gliosarcoma/química , Gliosarcoma/patología , Concentración 50 Inhibidora , Masculino , Trasplante de Neoplasias , Neutrones , Ratas , Ratas Wistar , Células Tumorales CultivadasRESUMEN
Adenovirus-mediated ex vivo gene transfer of basic fibroblast growth factor (bFGF), a new strategy for the treatment of chronic vascular occlusive disease, was examined in a rabbit model of hind limb ischemia. The left femoral artery was completely excised to induce an ischemic state in the hind limb of male rabbits. Simultaneously, a skin section was resected from the wound, and host fibroblasts were cultured. The cultured fibroblasts were infected with adenovirus vector containing modified human bFGF cDNA with the secretory signal sequence (AxCAMAssbFGF) or LacZ cDNA (AxCALacZ). At 21 days after femoral artery excision, the gene-transduced fibroblasts were administered through the left internal iliac artery. The fibroblasts significantly accumulated in the ischemic hind limb, and the AxCAMAssbFGF-treated cells secreted bFGF for less than 14 days without elevation of systemic bFGF level. At 28 days after cell administration, calf blood pressure ratio, angiographic score, capillary density of muscle tissue and blood flow of the left internal iliac artery were determined, and animals with AxCAMAssbFGF-treated cells showed significantly greater development of collateral vessels, as compared with those with AxCALacZ-treated cells. These findings suggest that adenovirus-mediated ex vivo gene transfer of bFGF was effective for improvement of chronic limb ischemia.
Asunto(s)
Adenoviridae/genética , Factor 2 de Crecimiento de Fibroblastos/genética , Terapia Genética/métodos , Vectores Genéticos/administración & dosificación , Miembro Posterior/irrigación sanguínea , Isquemia/terapia , Transducción Genética , Animales , Células Cultivadas , Enfermedad Crónica , Circulación Colateral , Fibroblastos , Expresión Génica , Humanos , Isquemia/fisiopatología , Hígado/metabolismo , Pulmón/metabolismo , Masculino , Modelos Animales , Músculo Esquelético/metabolismo , Conejos , Flujo Sanguíneo Regional , Factores de Tiempo , TransgenesRESUMEN
The calponin (basic or h1) gene, normally expressed in maturated smooth muscle cells, is aberrantly expressed in a variety of human soft tissue and bone tumors. In this study, we show that expression of the calponin gene in human soft tissue and bone tumor cells is regulated at the transcriptional level by the sequence between positions -260 and -219 upstream of the translation initiation site. A novel conditionally replicating herpes simplex virus-1 vector (d12.CALP) in which the calponin promoter drives expression of ICP4, a major trans-activating factor for viral genes was constructed and tested as an experimental treatment for malignant human soft tissue and bone tumors. In cell culture, d12.CALP at low multiplicity of infection (0.001 plaque-forming unit/cell) selectively killed calponin-positive human synovial sarcoma, leiomyosarcoma, and osteosarcoma cells. For in vivo studies, 10 animals harboring SK-LMS-1 human leiomyosarcoma cells were randomly divided and treated twice on days 0 and 9 intraneoplastically with either 1 x 10(7) plaque-forming units of d12.CALP/100 mm(3) of tumor volume or with medium alone. The viral treatment group showed stable and significant inhibition of tumorigenicity with apparent cure in four of five mice by day 35. Replication of viral DNA demonstrated by PCR amplification and expression of the inserted LacZ gene visualized by 5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside histochemistry was associated with oncolysis of d12.CALP-treated tumors, while sparing normal vascular smooth muscle cells. In mice harboring two SK-LMS-1 tumors, replication of d12.CALP was detected in a nontreated tumor distant from the site of virus inoculation. These results indicate that replication-competent virus vectors controlled by the calponin transcriptional regulatory sequence may be a new therapeutic strategy for treatment of malignant human soft tissue and bone tumors.
Asunto(s)
Neoplasias Óseas/genética , Proteínas de Unión al Calcio/genética , ADN de Neoplasias/genética , Terapia Genética , Regiones Promotoras Genéticas/genética , Neoplasias de los Tejidos Blandos/genética , Animales , Neoplasias Óseas/terapia , Chlorocebus aethiops , Femenino , Regulación Neoplásica de la Expresión Génica , Vectores Genéticos/genética , Humanos , Leiomiosarcoma/genética , Leiomiosarcoma/terapia , Ratones , Ratones Endogámicos BALB C , Ratones Desnudos , Proteínas de Microfilamentos , Osteoporosis/genética , Osteoporosis/terapia , Simplexvirus/genética , Neoplasias de los Tejidos Blandos/terapia , Transcripción Genética , Células Tumorales Cultivadas , Células Vero , Replicación Viral , Ensayos Antitumor por Modelo de Xenoinjerto , CalponinasRESUMEN
BACKGROUND: Bone morphogenetic proteins (BMPs) play important roles in the migration of osteoblast progenitor cells, the proliferation of mesenchymal cells, and their differentiation into chondrogenic and osteogenic cells. However, the optimum procedure to deliver BMPs remains unknown. To examine the effectiveness of a gene transfer procedure for the delivery of BMP-2, we constructed a human BMP-2-expressing replication-deficient adenoviral vector, AxCAOBMP-2, and evaluated its osteoinductive activity in vitro and in vivo. METHODS: C2C12 myoblasts were infected in vitro with this viral vector or an Escherichia coli LacZ gene-expressing control adenovirus vector (AxCALacZ). Twenty-four hours after the infection, indirect immunofluorescence was performed. On day 5 after the infection, alkaline phosphatase (ALP) in the cells and osteocalcin in the culture medium were measured. Furthermore, to examine the effectiveness of gene transfer of BMP-2 in vivo, we evaluated osteoinduction by AxCAOBMP-2, under transient immunosuppression with cyclophosphamide, given at a dose of 125 mg/kg intraperitoneally the day before injection of the adenoviral vector. Twenty-five microliters of AxCAOBMP-2 (8.75 x 10(8) plaque-forming units [pfu], Group I) and AxCALacZ (1.75 x 10(8) pfu, control group) and 5 microl of AxCAOBMP-2 (1.75 x 10(8) pfu, Group II) were injected into a right calf muscle of Wistar rats. On day 21, bone formation in each group was investigated radiologically and histologically. RESULTS: Abundant BMP-2 expression in C2C12 cells infected with this viral vector was confirmed by immunofluorescence. C2C12 cells transferred with the BMP-2 gene by this vector produced ALP in the cells and also produced and secreted osteocalcin in the culture medium. Osteoinduction was found only in the AxCAOBMP-2 treated groups with immunosuppression. Osteoinduction activity was higher in Group I than in Group II. CONCLUSION: This study demonstrated the osteoinductive activity in vitro and in vivo by an adenoviral vector carrying the BMP-2 gene. CLINICAL RELEVANCE: Gene therapy with AxCAOBMP-2 under transient immunosuppression may be useful for bone reconstruction.
Asunto(s)
Adenoviridae , Proteínas Morfogenéticas Óseas/genética , Técnicas de Transferencia de Gen , Vectores Genéticos , Osteogénesis , Factor de Crecimiento Transformador beta , Fosfatasa Alcalina/metabolismo , Animales , Proteína Morfogenética Ósea 2 , Proteínas Morfogenéticas Óseas/biosíntesis , Línea Celular , Células Cultivadas , Técnica del Anticuerpo Fluorescente Indirecta , Técnicas In Vitro , Masculino , Músculo Esquelético/citología , Músculo Esquelético/metabolismo , Osteoblastos/citología , Osteoblastos/metabolismo , Osteocalcina/biosíntesis , Ratas , Ratas WistarRESUMEN
Cerebral ischemic disease often causes morbidity and mortality, while the induction of new blood vessels is expected to provide a therapeutic effect in this occlusive cerebrovascular disease. In this study, we utilized two replication-deficient adenoviral vectors containing cDNA from basic fibroblast growth factor (bFGF), a well-known angiogenic factor, and examined whether biological angiogenic activity of adenovirally gene-transferred bFGF could be observed in the rat brain. One vector contained native cDNA from bFGF without the secretory signal sequence and the other contained the same cDNA fused with an interleukin-2 secretory signal sequence. After ventricular administration of these viral vectors, gene-transferred cells demonstrated a high immunoreactivity against the anti-bFGF antibody and a remarkably high concentration of bFGF was detected in the cerebrospinal fluid. A semiquantitative analysis of angiogenic activity revealed that bFGF gene transfer induced angiogenesis in normal rat brains, with a more pronounced angiogenic effect seen with the vector of a secreted form than with the vector without a secretory signal sequence. These results suggest that bFGF gene transfer using these adenoviral vectors might be useful for the treatment of ischemic cerebrovascular disease.
Asunto(s)
Adenoviridae/genética , Encéfalo/irrigación sanguínea , Factor 2 de Crecimiento de Fibroblastos/genética , Terapia Genética/métodos , Vectores Genéticos/administración & dosificación , Neovascularización Fisiológica/genética , Animales , Encéfalo/metabolismo , Ensayo de Inmunoadsorción Enzimática/métodos , Factor 2 de Crecimiento de Fibroblastos/análisis , Expresión Génica , Inmunohistoquímica , Masculino , Ratas , Ratas Wistar , Transfección/métodosRESUMEN
To examine the effectiveness of gene transfer of bone morphogenetic protein (BMP)-2 in vivo, we evaluated osteoinduction by an adenoviral vector, AxCAOBMP-2, under transient immunosuppression with an immunosuppression drug (cyclophosphamide), which was given at a dose of 125 mg/kg intraperitoneally the day before vector injection. Twenty-five microliters of AxCAOBMP-2 (8.75 x 10(8) pfu, Group I) and AxCALacZ (1.75 x 10(8) pfu, control group) and 5 microliter of AxCAOBMP-2 (1.75 x 10(8) pfu, Group II) were injected into a right calf muscle. On day 21, induced bone in each group was investigated radiologically, histologically, and biochemically. The finding of osteoinduction was only seen in the AxCAOBMP-2-treated groups with immunosuppression. The activity of osteoinduction in Group I was higher than that in Group II. These results suggest that gene therapy with AxCAOBMP-2 under transient immunosuppression may be useful for bone reconstruction.
Asunto(s)
Proteínas Morfogenéticas Óseas/genética , Ciclofosfamida/farmacología , Técnicas de Transferencia de Gen , Osteogénesis , Factor de Crecimiento Transformador beta , Adenoviridae , Fosfatasa Alcalina/análisis , Animales , Proteína Morfogenética Ósea 2 , Proteínas Morfogenéticas Óseas/biosíntesis , Terapia Genética/métodos , Vectores Genéticos , Terapia de Inmunosupresión/métodos , Masculino , Músculo Esquelético/citología , Músculo Esquelético/diagnóstico por imagen , Radiografía , Ratas , Ratas Wistar , beta-Galactosidasa/biosíntesis , beta-Galactosidasa/genéticaRESUMEN
BACKGROUND AND PURPOSE: The proliferation of vascular smooth muscle cells (VSMCs) is a common feature associated with vascular proliferative disorders such as atherosclerosis and restenosis after balloon angioplasty. We examined the antiproliferative effects of recombinant replication-competent herpes simplex virus (HSV), hrR3, to proliferative VSMCs both in vitro and in vivo. METHODS: Early passages of Sprague-Dawley rat VSMCs were infected with hrR3 at a low multiplicity of infection (0.01 to 1.0) to examine the in vitro cytotoxic activity of this recombinant HSV to VSMCs in a proliferative state. Sprague-Dawley rats underwent balloon dilatation injury of the left carotid artery to induce neointimal formation. The injured carotid arteries were infected with hrR3 five days after balloon injury. Two weeks after injury, the left carotid arteries were fixed, and the areas of the neointimal and medial layers were analyzed microscopically. Because the reporter Escherichia coli lacZ gene in hrR3 is expressed only in infected cells in which the virus is actively replicating, virus replication was confirmed by X-gal staining. RESULTS: A morphometric analysis revealed that there were significant differences in the intima/media ratio between the HSV-treated group and mock-infected group (0. 354+/-0.068 and 1.08+/-0.055, respectively). In the histological study (X-gal staining), positive X-gal staining was observed chiefly in the VSMCs in the medial layer just beneath the internal elastic lamina, indicating active viral replication. CONCLUSIONS: Virus-mediated cytocidal therapy using recombinant HSV vector is a promising modality for the treatment of the restenosis after balloon angioplasty.
Asunto(s)
Músculo Liso Vascular/virología , Simplexvirus/fisiología , Angioplastia de Balón/efectos adversos , Animales , Arterias Carótidas/patología , Arterias Carótidas/virología , Enfermedades de las Arterias Carótidas/patología , División Celular , Células Cultivadas , Compuestos Cromogénicos , Tejido Elástico/patología , Tejido Elástico/virología , Endotelio Vascular/patología , Endotelio Vascular/virología , Escherichia coli/genética , Galactósidos , Genes Reporteros/genética , Hiperplasia , Inmunohistoquímica , Indoles , Antígeno Ki-67/análisis , Operón Lac/genética , Músculo Liso Vascular/patología , Ratas , Ratas Sprague-Dawley , Recurrencia , Simplexvirus/genética , Túnica Íntima/patología , Túnica Íntima/virología , Túnica Media/patología , Túnica Media/virología , Replicación Viral/genética , beta-Galactosidasa , Factor de von Willebrand/análisisRESUMEN
Targeting viral vectors to appropriate cell types so that normal cells are not adversely affected is an important goal for gene therapy. Previously, we described a novel approach to viral gene therapy using a conditional, replication-competent herpes simplex virus (HSV), where replication and associated cytotoxicity are limited to a specific cell-type by the regulated expression of an essential immediate-early viral gene product. In this report we analyze the hepatoma-specific replication, cytotoxicity and anti-tumor effect of recombinant HSV G92A, regulated by the albumin enhancer/promoter. G92A efficiently replicated in vitro in two human hepatoma cell lines expressing albumin, but not in four human non-hepatoma, albumin-non-expressing tumor cell lines, while all cell lines were equally susceptible to a tissue nonspecific HSV recombinant, hrR3. In vivo, G92A replicated well in subcutaneous xenografts of human hepatoma cells (Hep3B) in athymic mice, but not in non-hepatoma subcutaneous tumors (PC3 and HeLa), whereas, hrR3 replicated well in both tumor types. Intratumoral inoculation of G92A inhibited the growth of established subcutaneous hepatoma tumors in nude mice, but not prostate tumors. Replication-competent viral vectors controlled by cell-specific transcriptional regulatory sequences provide a new therapeutic strategy for tumor therapy.
Asunto(s)
Carcinoma Hepatocelular/terapia , Terapia Genética/métodos , Vectores Genéticos/administración & dosificación , Neoplasias Hepáticas Experimentales/terapia , Simplexvirus/genética , Transfección/métodos , Albúminas/genética , Animales , Elementos de Facilitación Genéticos , Femenino , Humanos , Ratones , Ratones Endogámicos BALB C , Células Tumorales Cultivadas , Replicación ViralRESUMEN
Vascular smooth muscle cell (VSMC) proliferation associated with arterial injury causes restenosis, which remains to be resolved in cardiovascular and ischemic cerebrovascular disease, especially after balloon angioplasty. Fibroblast growth factor (FGF) is a potent mitogen and a trophic factor for a variety of cells, including VSMCs. We constructed a replication-deficient adenovirus vector, designated AxCA delta FR, coding a truncated form of fibroblast growth factor receptor-1 (FGFR-1) gene lacking the intracellular domain to interrupt receptor-mediated FGF signaling, and examined its effect on the proliferation of primary-cultured rat VSMCs. We transferred the truncated form of the FGFR-1 gene to the VSMCs and confirmed its expression and localization in infected cells by Western blotting and immunofluorescence study. The VSMCs infected with AxCA delta FR degenerated and the proliferation of these cells was suppressed markedly by the infection with this virus in vitro. Our results suggest that the receptor-mediated signal of FGFs has an important role in VSMC proliferation and gene transfer of a truncated form of FGFR using adenoviral vector may be useful for the treatment of the diseases caused by excessive proliferation of VSMCs like restenosis after percutaneous transluminal angioplasty or carotid endoarterectomy.
Asunto(s)
Técnicas de Transferencia de Gen , Músculo Liso Vascular/citología , Receptores de Factores de Crecimiento de Fibroblastos/genética , Receptores de Factores de Crecimiento de Fibroblastos/fisiología , Adenoviridae , Animales , Arteriosclerosis/fisiopatología , Arteriosclerosis/terapia , Western Blotting , División Celular , Técnica del Anticuerpo Fluorescente Indirecta , Terapia Genética , Vectores Genéticos , Técnicas In Vitro , Músculo Liso Vascular/química , Ratas , Ratas Sprague-Dawley , Receptores de Factores de Crecimiento de Fibroblastos/análisisRESUMEN
The mechanism by which tumour necrosis factor (TNF)-alpha increases the susceptibility of U87-MG human glioblastoma cells to lysis by natural killer (NK) cells was studied. Treatment with TNF-alpha (100 units ml-1) for 48 h enhanced the susceptibility of tumour cells to lysis by NK cells. Increased susceptibility to lysis was associated with enhanced expression of intercellular adhesion molecule 1 (ICAM-1) and HLA class I antigen. Antisense ICAM-1 oligonucleotide inhibited lysis by NK cells of TNF-alpha-treated tumour cells. In contrast, acid treatment following TNF-alpha treatment increased lysis by NK cells. These findings indicate that TNF-alpha treatment of glioblastoma cells increased their susceptibility to lysis by NK cells, since ICAM-1 up-regulation would have more profound effects on NK susceptibility than would HLA class I antigen up-regulation.